Nanjing Second Hospital

Running trials

• Recruiting

  A Study of CS0159 in Patients With PBC With Inadequate Response or Intolerance to UDCA

  NCT07282353· Phase 3· Source

• Recruiting

  GKL-006 Injection Plus TACE Versus TACE Alone in Patients With Unresectable Hepatocellular Carcinoma

  NCT07209813· Phase 2· Source

• Active, not recruiting

  A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection

  NCT07245953· Phase 2· Source

• Recruiting

  A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis

  NCT07209761· Phase 3· Source

• Recruiting

  A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets

  NCT07170800· Phase 2· Source

• Not yet recruiting

  A Study to Predict Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness and Simple Blood Tests

  NCT07087041· Source

• Not yet recruiting

  Real-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer

  NCT07007286· Source

• Active, not recruiting

  Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis：BDLL Chinese Cohort

  NCT06649721· Phase 3· Source

• Recruiting

  LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· Phase 3· Source

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Source

• Active, not recruiting

  Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort

  NCT06081361· Phase 3· Source

• Recruiting

  Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

  NCT06051617· Phase 3· Source

• Active, not recruiting

  Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis

  NCT06174402· Phase 2/3· Source

• Active, not recruiting

  A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

  NCT04849728· Phase 3· Source

• Active, not recruiting

  A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)

  NCT04344158· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)3 recruiting
• Hepatitis B2 recruiting
• Liver and biliary tract cancer2 recruiting
• Primary biliary cholangitis2 recruiting
• Tuberculosis2 recruiting
• High blood pressure1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Withdrawn

  A Clinical Trial to Evaluate the Efficacy and Safety of TQA3605 Tablets in Treatment-naive Chronic HBV-infected Subjects

  NCT06990776· Phase 2· Source

• Completed

  A Phase II Clinical Trial of Chiglitazar for NASH

  NCT05193916· Phase 2· Source

• Completed

  Efficacy and Safety Study of Peginterferon Alfacon-2 to Treat Chronic Hepatitis B Virus Infection

  NCT06544551· Phase 3· Source

• Completed

  A Phase II Study of Hepalatide in Subjects With Chronic Hepatitis B

  NCT04426968· Phase 2· Source

• Completed

  A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

  NCT04771273· Phase 2· Source

• Completed

  Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naive, HIV-1 and Hepatitis B Co-Infected Adults

  NCT03547908· Phase 3· Source

Trial sites

• Nanjing Second Hospital5 trials
• Second Hospital of Nanjing1 trial
• The Second Hospital of Nanjing15 trials

Conditions

Diseases this institution publishes on or runs trials for.

• Hepatitis B10 works · 7 trials
• Primary biliary cholangitis5 works · 3 trials